(Q34277542)

1 August 2017

Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers (English)

1 reference

1 August 2017

Multiple-Dose Administration of Ginkgo biloba Did Not Affect Cytochrome P-450 2D6 or 3A4 Activity in Normal Volunteers (English)

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

3 April 2024

0 references

5

Kenneth D. Chavin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624188

3 April 2024

author name string

Laura Sipkes

4

1 reference

1 August 2017

John S. Markowitz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624188

3 April 2024

Jennifer L. Donovan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624188

3 April 2024

C. Lindsay DeVane

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624188

3 April 2024

language of work or name

English

0 references

publication date

1 December 2003

1 reference

full work available at URL

1 August 2017

https://journals.lww.com/10.1097/01.jcp.0000095340.32154.c6

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Journal of Clinical Psychopharmacology

3 April 2024

published in

1 reference

1 August 2017

23

1 reference

1 August 2017

576-581

1 reference

1 August 2017

6

1 reference

Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey

1 August 2017

2

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Pharmaceutical quality of different Ginkgo biloba brands

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Ginkgo biloba for cerebral insufficiency

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Drug-Metabolizing Enzymes and Therapeutic Drug Monitoring in Psychiatry

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Human cytochrome P450s: selectivity and measurement in vivo

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Alprazolam is another substrate for human cytochrome P450-3A isoforms.

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Clinical pharmacokinetics of alprazolam. Therapeutic implications

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Cognitive factors and the use of over-the-counter medication organizers by arthritis patients

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Modified high-performance liquid chromatographic method to measure both dextromethorphan and proguanil for oxidative phenotyping

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Alprazolam, alpha-hydroxy- and 4-hydroxyalprazolam analysis in plasma by high-performance liquid chromatography

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

Alprazolam-ritonavir interaction: implications for product labeling

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095340.32154.C6

3 April 2024

Identifiers

1 reference

1 August 2017

1 reference